2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009

Purple Haze Properties (PHP) & Cannabis Science (CBIS) Announce Successful Launch of Hendrix-Themed Cannabis Theraputic Products

Purple Haze Properties (PHP) & Cannabis Science (CBIS) Announce Successful Launch of Hendrix-Themed Cannabis Therapeutic Products

"Jimi's Meds" Now Available in the State of California

LOS ANGELES, CA--(Marketwired - Feb 24, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to announce Purple Haze Properties LLC www.purplehazeproperties.com, created by Andrew Pitsicalis and Leon Hendrix, have partnered with Cannabis Science to create Jimi Hendrix themed cannabis supplements. Powered by Cannabis Science, "Jimi's Meds" has many varieties and dosages to accommodate various medicinal and personal needs, recently made available in the State of California through the www.jimismeds.com website.

"I wish my uncle, Jimi Hendrix, was alive to see these products helping so many people; it was such a great experience being at our Cannabis Cup booth earlier this month. Seeing all the patients and fans embracing our products was a beautiful eye opener. As well, meeting Mr. Dabney for the first time was a pleasure, and I can see the success our partnership can enjoy by using our combined resources to get our products out there for all to benefit," stated James J Hendrix.

Purple Haze Properties Co-Founders, Andrew Pitsicalis & Leon Hendrix, commented, "We have created 3 tiers of dosages, a 10mg, 25mg, and 50mg structure. Depending on the severity of the ailment, the patient would take the recommended dose to help alleviate their symptom. At this year's Cannabis Cup, 'Jimi's Meds' had two entries this year, and we received lots of great feedback from the Judges who came to our booth during the event. One Judge said, 'The 50mg CBD/THCA blend combined with the 25mg Pure THC pill, helped her enjoy the event the entire day without pain or discomfort from her chronic condition.' We had our 10/10 CDB & THCA Full Spectrum Blends for sale in, 10 Day and 30 Day supplies. We also debuted our 25mg, Pure THC capsules mainly to tackle pain relief. A non-psychoactive blend of CBD + THCa is now available as well as a non-psychoactive raw CBD therapy. We also introduced a psychoactive pure THC supplement. All of our products are created from oil made from organically grown strain-specific cannabis flowers."

"Jimi's Meds" are only available at this time for California licensed Medical Marijuana Patients. Verified Patients can upload their doctor's prescription, medical information, and place their orders online at the www.jimismeds.com website.

Purple Haze Properties, LLC was founded through a partnership between Andrew Pitsicalis and Leon Hendrix, blood brother to the legendary guitar icon, Jimi Hendrix. Purple Haze Properties, LLC is one of the premiere sources for Jimi Hendrix cannabis related products. They participate in all aspects of the cannabis industry including Licensing, Social, Medical, Music and Entertainment areas. The company also provides support for Jimi's surviving nieces and nephews.

For more information, visit:
or email: This email address is being protected from spambots. You need JavaScript enabled to view it.

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.